Pneumococcal Conjugate Vaccine Protection against Coronavirus-Associated Pneumonia Hospitalization in Children Living with and without HIV
Marta C. Nunes, Clare Cutland, Keith P. Klugman, Shabir A. Madhi
Abstract
SARS-CoV-2 may cause severe hospitalization, but little is known about the role of secondary bacterial infection in these severe cases, beyond the observation of high levels of reported inflammatory markers, associated with bacterial infection, such as procalcitonin. We did a secondary analysis of a double-blind randomized trial of PCV to examine its impact on human CoV infections before the pandemic. We found that both children living with and without HIV randomized to receive PCV had evidence of less hospitalization due to seasonal CoV, suggesting that pneumococcal coinfection may play a role in severe hospitalized CoV infections.
Topics & Concepts
PneumoniaMedicinePneumococcal conjugate vaccineVirologyCoronavirusCoronavirus disease 2019 (COVID-19)Pneumococcal pneumoniaHuman immunodeficiency virus (HIV)Streptococcus pneumoniaeConjugate vaccine2019-20 coronavirus outbreakPandemicSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ImmunologyImmunizationMicrobiologyBiologyImmune systemInfectious disease (medical specialty)DiseaseAntibioticsInternal medicineOutbreakPneumonia and Respiratory InfectionsSARS-CoV-2 and COVID-19 ResearchRespiratory viral infections research